Galvus Met

Galvus Met

vildagliptin + metformin

Manufacturer:

Novartis

Distributor:

Zuellig Pharma

Marketer:

A.Menarini
Concise Prescribing Info
Contents
Per 50 mg/500 mg FC tab Vildagliptin 50 mg, metformin HCl 500 mg. Per 50 mg/1,000 mg FC tab Vildagliptin 50 mg, metformin HCl 1,000 mg
Indications/Uses
Adjunct to diet & exercise to improve glycemic control in patients w/ type 2 DM as initial therapy when diabetes is not adequately controlled by diet & exercise alone or as therapy in patients inadequately controlled w/ metformin HCl or vildagliptin alone or who are already treated w/ combination of vildagliptin & metformin HCl as separate tab. In combination w/ other medicinal products for diabetes, including insulin, when these do not provide adequate glycemic control.
Dosage/Direction for Use
Individualized dose. Max vildagliptin dose: 100 mg. Inadequately controlled on vildagliptin monotherapy Initially 50 mg/500 mg bid & titrate gradually after assessing adequacy of therapeutic response. Inadequately controlled on metformin HCl monotherapy Initially 1 tab bid, based on current metformin dose. Switching from combination of vildagliptin plus metformin as separate tab 1 tab, based on current dose of vildagliptin or metformin. Treatment naive patient Initially 50 mg/500 mg once daily & titrate gradually to a max dose of 50 mg/1,000 mg bid after assessing adequacy of therapeutic response. In combination w/ SU or insulin 50 mg bid vildagliptin dose & the current metformin dose.
Administration
Should be taken with food: Take w/ or immediately after meals to reduce GI discomfort.
Contraindications
Hypersensitivity. Renal disease or dysfunction (GFR <30 mL/min), CHF, metabolic acidosis.
Special Precautions
Discontinue in case of hypoxic states. Not to be used in type 1 DM or diabetic ketoacidosis, hepatic impairment, pre-treatment ALT or AST >2.5x ULN, lactic acidosis, surgical procedures, hypoglycaemia, loss of blood glucose control. Monitor hepatic enzyme, renal function & serum vit B12. Avoid excessive alcohol intake. Pregnancy & lactation. Childn <18 yr. Elderly (monitor renal function).
Adverse Reactions
Nausea, vomiting, diarrhea, abdominal pain, decreased appetite, GERD, tremor, dizziness, headache, asthenia, hypoglycemia, hyperhidrosis, chills, decreased blood glucose, dysgeusia, flatulence.
Drug Interactions
Metformin: Increased exposure w/ furosemide, nifedipine, ranolazine, vandetanib, dolutegravir, cimetidine. Concomitant use w/ iodinated contrast agents. May lead to loss of glycemic control w/ thiazides & other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, OC, phenytoin, nicotinic acid, sympathomimetics, Ca-channel blockers, INH.
MIMS Class
Antidiabetic Agents
ATC Classification
A10BD08 - metformin and vildagliptin ; Belongs to the class of combinations of oral blood glucose lowering drugs. Used in the treatment of diabetes.
Presentation/Packing
Form
Galvus Met FC tab 50 mg/1,000 mg
Packing/Price
6 × 10's
Form
Galvus Met FC tab 50 mg/500 mg
Packing/Price
6 × 10's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in